- BioNTech (BNTX, Financial) and Bristol Myers Squibb (BMY) enter a global partnership for BNT327.
- Bristol Myers Squibb will pay $1.5 billion upfront and $2 billion through 2028.
- BNT327 is in Phase 3 trials for lung cancer and pending trial for breast cancer by 2025.
BioNTech SE (BNTX) and Bristol Myers Squibb (BMY) have announced a comprehensive global strategic partnership to co-develop and co-commercialize BNT327, a next-generation bispecific antibody targeting PD-L1 and VEGF-A designed to treat multiple solid tumor types. This collaboration aims to accelerate BNT327's clinical development and potential market entry.
Under the agreement, Bristol Myers Squibb will make an upfront payment of $1.5 billion to BioNTech, with an additional $2 billion in non-contingent payments expected by 2028. Moreover, BioNTech could receive up to $7.6 billion in milestone payments contingent on development, regulatory, and commercial goals.
BNT327 is being tested in more than 20 clinical trials involving over 1,000 patients, including ongoing Phase 3 trials for small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). A Phase 3 trial for triple negative breast cancer (TNBC) is planned for initiation by the end of 2025.
This partnership embodies a 50:50 cost and profit-sharing model, showcasing a firm mutual commitment to harness both companies' expertise in immuno-oncology to establish BNT327 as a foundational treatment alternative across various oncology indications.
